A biotech used CRISPR to remove the main dog allergen from two beagles. The science is real, and so are the limits.

Two beagles, Alfie and Bailey, came from a single edited skin cell. Kindred Companion Sciences inserted an extra DNA letter at the start of the gene that makes Can f 1, the main protein that drives dog allergies, and then cloned that cell. The result is a CRISPR-Cas9 frameshift in a mammalian allergen gene, demonstrated end to end in a companion animal. (New Scientist)

Kindred's published study shows Can f 1 is undetectable in saliva, skin, and fur samples from both dogs, and skin-prick tests with their samples do not provoke reactions in people sensitive to standard dogs. Normal-dog samples do. (Wired) (AP) The result is the first peer-credible demonstration of a mammalian allergen knocked out at the gene level in a living animal.

The mechanism matters because Can f 1 is the workhorse of dog allergies, not just one of many. It is the protein most dog-allergic patients react to first, and it is secreted by the tongue and skin glands, so it lands on fur, dander, and saliva in roughly equal measure. Kindred disrupted the gene that encodes it. CRISPR-Cas9 was used to cut the DNA at the start of Can f 1, and when the cell repaired the cut, an extra base was added. That one-letter insertion shifts the reading frame downstream, so the rest of the protein recipe reads as nonsense and no functional protein is made. (New Scientist)

The two dogs are the product of a deliberate, low-throughput path. Kindred took skin cells from a female beagle, edited them, confirmed the on-target edit and the absence of off-target mutations, then transferred the nucleus of each edited cell into an egg via somatic cell nuclear transfer, the same cloning technique used to make Dolly the sheep. Twenty-five embryos were implanted into a surrogate; two carried to term. Alfie and Bailey are now nearly two years old, and Kindred reports both are healthy. (GEN)

The ceiling is closer than the headline suggests. Can f 1 is the major allergen, not the only one. Dogs also produce Can f 2, Can f 3, and others, and most allergic patients react to more than one. Kindred has not yet edited those. He told reporters the company could add further edits later if a substantial responder population is identified, meaning patients whose symptoms are driven mostly by Can f 2 rather than Can f 1. (New Scientist)

Welfare is the harder question. The normal function of Can f 1 in dogs is not fully characterized. Walker points to mouse knockouts of the same gene family as the basis for expecting no problems; two animals, both under two years old, is a thin dataset against a mammalian lifespan of more than a decade. A founder who shares a home with one of the animals is also the person whose company is selling the platform, and the only on-record human source in the available reporting. A wider picture of the dogs' health across years, and an independent read on whether Can f 1's function matters in dogs, are both still open. (AP)

The result opens a tractable pattern, not a product. Knocking out one major allergen in a mammal is now demonstrable in a companion animal, and the limit is no longer molecular. The next test is whether the platform extends: cats, where the dominant allergen is Fel d 1 and the market case is larger, and the residual allergens in dogs that the current pair still produces. The next paper will test whether Can f 2 follows Can f 1; the next several years will test whether Alfie and Bailey stay healthy. Without both, the result is a demonstration of a frameshift in one mammalian allergen, not a route to allergy-free dogs.